Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Treatment of Low-Risk Submassive Pulmonary Embolism With FlowTriever

NCT: NCT05273762 · RECRUITING

NCT IDNCT05273762
StatusRECRUITING
Start Date2022-01-25
Completion2027-07-25
SponsorNorthwell Health (OTHER)
First posted
Last updated

Brief Summary

This study is focused on investigating the efficacy and safety of the FlowTriever device to treat low-risk submassive pulmonary embolism.

Frequently Asked Questions

What is Treatment of Low-Risk Submassive Pulmonary Embolism With FlowTriever?

Treatment of Low-Risk Submassive Pulmonary Embolism With FlowTriever is a clinical trial registered under NCT05273762. Current status: RECRUITING.

What is the status of NCT05273762?

The current status of NCT05273762 (Treatment of Low-Risk Submassive Pulmonary Embolism With FlowTriever) is: RECRUITING.

When did Treatment of Low-Risk Submassive Pulmonary Embolism With FlowTriever start?

Treatment of Low-Risk Submassive Pulmonary Embolism With FlowTriever started on 2022-01-25.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑